Poland· PL-100505961
Lurobran
A lurasidone product containing lurasidonum, registered in Poland by Exeltis Poland Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lurasidone is registered in 16 of 19 countries.
Countries holding a registration under ATC N05AE05 (lurasidone), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Lurasidone · ATC N05AE05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lurasidone costs, country by country.
Normalised to the WHO defined daily dose (60 mg), the median price runs from $2.63 in Italy to $6.45 in Switzerland — a ×2.4 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lurasidone · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$6.45
- IT Italy$2.63
The record
At a glance
URPL (Poland)- Active substance
- Lurasidonum
- Manufacturer
- Exeltis Poland Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N05AE05
- ATC class
- Lurasidone
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991576479
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
242 interactions on record for lurasidone.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lurasidone · interactions on record
242 records
- 32 severe
- 205 moderate
Most severe, free to view
- MetoclopramideA03FA01severe
- AprepitantA04AD12severe
- KetoconazoleH02CA03severe
- ErythromycinJ01FA01severe
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lurasidone in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaISAQExeltis Czech s.r.o., Praha
- SpainLUROBRAN 148 MG COMPRIMIDOS RECUBIERTOS CON PELICULAExeltis Healthcare S.L.
- SwedenLurobran 148 mg Filmdragerad tablettExeltis Healthcare, S.L.
- United StatesLatudaSumitomo Pharma America, Inc.
- CanadaAURO-LURASIDONEAURO PHARMA INC
- United KingdomLatuda 18.5mg tabletsCNX Therapeutics Ltd
- ItalyLATUDAANGELINI S.P.A.
- FinlandLatudaAbacus Medicine A/S
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Lurasidon G.L., Lurasidon Genericon
- Bulgaria · Lurasidone Accord, Луразидон Тева
- Czechia · Isaq, Lurasidon G.L. Pharma
- Germany · Lurasidon Elpen
- Denmark · Elgera, Lurasidone Accord
- Spain · Lurasidona Cinfa, Lurasidona Tecnigen
- Finland · Lurasidone Accord
- United Kingdom (Northern Ireland) · Lurasidone Accord Healthcare, Lurasidone Amarox
- Greece · Elgera, Latomno
- Croatia · Lurasidon Teva
- Iceland · Latuda
- Italy · Lurasidone Accord, Lurasidone Doc
- Liechtenstein · Latuda
- Netherlands · Lurasidon Teva
- Norway · Latuda, Lurasidone Accord
- Portugal · Latomno, Lurasidona Farmoz
- Sweden · Lurasidon G.L. Pharma, Lurasidone Accord
- Slovenia · Lurasidon Teva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a859c3d8-c1c9-430e-862d-fdf0f64d90b5 GET /v1/drugs/a859c3d8-c1c9-430e-862d-fdf0f64d90b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "148 mg",
"packaging": "05909991576479 ¦ Rp ¦ 162275\n28 tabl.",
"substance": "Lurasidonum 149 mg",
"common_name": "Lurasidonum",
"pl_product_id": "100505961",
"pozwolenie_nr": "29011",
"auth_procedure": "DCP",
"authorisation_validity": "2030-05-29"
}See everything about lurasidone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.